
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure is a rapidly growing oncology company with a promising pipeline and key technologies, such as TTFields devices and Optune, that have shown strong potential for the treatment of various solid tumor cancers. While there are risks associated with clinical failures and slower sales/adoption of their products, potential M&A activity and clinical de-risking could lead to upside potential. Our neutral rating and $18 price target are based on a sum-of-parts valuation that factors in the company's current sales and royalties, as well as a discounted multiple for their pipeline products in different indications.
Bears say
NovoCure is projected to have a low-to-mid single-digit growth in GBM, with modest contributions from lung and pancreatic indications. However, there are concerns about limited adoption of Optune Lua in NSCLC and modest near-term contributions from Optune PAX in pancreatic cancer due to competition, reimbursement timelines, and modest survival benefits. This, coupled with potential risks and downside factors such as poor sales/adoption and clinical failures, lead us to have a negative outlook on the stock.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares